The clinical trial is timely and will enroll 1000 individuals age 70 and older in France starting in 2024. It will test a personalized intervention that strengthens the six ICOPE functions (mobility, cognition, mental health, vision, hearing and nutrition/vitality) is successful in preventing functional decline over 3 years.

The trial will be the largest and longest trial to prove the effectiveness of the WHO ICOPE program and will thereby have a global impact to advance healthy longevity. To support health policy makers in the broad dissemination of ICOPE, the trial will assess the socio-economic impact of the intervention.

Additionally, the trial will build a biobank to use the trial as a workbench for novel biomarker validation discovered in the IHU pillar 2 and by international scientific and industry partners of the IHU.